Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

INTRODUCTION. Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), may underestimate activity and does not predict survival in patients with hepatocellular carcinoma (HCC) treated with sorafenib. This study assessed the value of alternative radiological criteria to evaluate respon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ronot, Maxime, Bouattour, Mohamed, Wassermann, Johanna, Bruno, Onorina, Dreyer, Chantal, Larroque, Béatrice, Castera, Laurent, Vilgrain, Valérie, Belghiti, Jacques, Raymond, Eric, Faivre, Sandrine
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2014
Matèries:
Hepatobiliary
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983809/
https://ncbi.nlm.nih.gov/pubmed/24652387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars